Lu-177-XT033
177Lu-XT033 is a PSMA targeting radiotherapeutic developed for the treatment [...]
Lu-177-LNC1010
177Lu-LNC1010 is a new radiolabeled drug targeting somatostatin receptors (sstr), [...]
Lu-177-LNC1004
177Lu-LNC1004 is a new radiolabeled drug targeting fibroblast activation protein [...]
Lu-177-ITM-31
177Lu-ITM-31 (177Lu-LuCaFab) is a carbonic anhydrase XII-specific antibody Fab fragment. [...]
Lu-177-DPI-4452
177Lu-DPI-4452 is a 177Lu labeled peptide developed for the treatment [...]
Lu-177-DOTA-EB-FAPi
177Lu-DOTA-EB-FAPi is a new therapeutic agent from the FAPi family. [...]
Lu-177-AMTG
177Lu-AMTG is a radiolabeled bombesin analogue developed at the Technical [...]
Lu-177-HTK03170
177Lu-HTK03170 is the therapeutic 177Lu-labeled analogue of 68Ga-HTK03149, itself based [...]
Lu-177-Rituximab
177Lu-Rituximab is the Lutetium-177 labeled analogue of 131I-Tositumomab (131I-Bexxar) for [...]
Lu-177-PSMA-ALB-56
177Lu-PSMA-ALB-56 is a radiolabeled PSMA analogue developed for prostate cancer [...]